Role of Finerenone in the Treatment of Diabetic Kidney Disease : Patient Selection and Clinical Perspectives
© 2022 Shaikh et al..
Diabetes is the leading cause of chronic and end stage kidney disease globally. Despite recent advances in therapies for diabetic kidney disease (DKD), there remains a critical need for additional options to improve renal and cardiovascular outcomes. Mineralocorticoid overactivation contributes to inflammation and fibrosis which in turn leads to progression of DKD. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has shown promising cardiac and renoprotective benefits in DKD. The utility of finerenone in the real world will require appropriate patient selection and patient monitoring by clinicians.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Therapeutics and clinical risk management - 18(2022) vom: 30., Seite 753-760 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shaikh, Aisha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic kidney disease |
|---|
| Anmerkungen: |
Date Revised 30.09.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/TCRM.S325916 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344574288 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344574288 | ||
| 003 | DE-627 | ||
| 005 | 20231226023101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/TCRM.S325916 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344574288 | ||
| 035 | |a (NLM)35937973 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shaikh, Aisha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of Finerenone in the Treatment of Diabetic Kidney Disease |b Patient Selection and Clinical Perspectives |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.09.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 Shaikh et al. | ||
| 520 | |a Diabetes is the leading cause of chronic and end stage kidney disease globally. Despite recent advances in therapies for diabetic kidney disease (DKD), there remains a critical need for additional options to improve renal and cardiovascular outcomes. Mineralocorticoid overactivation contributes to inflammation and fibrosis which in turn leads to progression of DKD. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has shown promising cardiac and renoprotective benefits in DKD. The utility of finerenone in the real world will require appropriate patient selection and patient monitoring by clinicians | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a finerenone | |
| 700 | 1 | |a Ray, Justina |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Kirk N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutics and clinical risk management |d 2005 |g 18(2022) vom: 30., Seite 753-760 |w (DE-627)NLM178434906 |x 1176-6336 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g day:30 |g pages:753-760 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/TCRM.S325916 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |b 30 |h 753-760 | ||